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The tripartite motif (TRIM) protein, TRIM5a, restricts infection by particular retroviruses. Many TRIM proteins form cytoplasmic bodies
of unknown function. We investigated the relationship between cytoplasmic body formation and the structure and antiretroviral activity of
TRIM5a. In addition to diffuse cytoplasmic staining, the TRIM5a proteins from several primate species were located in cytoplasmic bodies
of different sizes; by contrast, TRIM5a from spider monkeys did not form cytoplasmic bodies. Despite these differences, all of the
TRIM5a proteins exhibited the ability to restrict infection by particular retroviruses. Treatment of cells with geldanamycin, an Hsp90
inhibitor, resulted in disappearance or reduction of the TRIM5a-associated cytoplasmic bodies, yet exerted little effect on the restriction of
retroviral infection. Studies of green fluorescent protein-TRIM5a fusion proteins indicated that no TRIM5a domain is specifically required
for association with cytoplasmic bodies. Apparently, the formation of cytoplasmic bodies is not required for the antiretroviral activity of
TRIM5a.
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Following entry into the host cell, prior to reverse
transcription, some retroviruses encounter blocks in the cells
of particular species (Bieniasz, 2003; Himathongkham and
Luciw, 1996; Hofmann et al., 1999; Shibata et al., 1995; Stoye,
2002). For example, human immunodeficiency virus (HIV-1)
encounters a postentry block in Old World monkeys, whereas
simian immunodeficiency virus of macaques (SIVmac) is
blocked in most New World monkey cells (Hofmann et al.,
1999). These blocks are mediated by TRIM5a, and inter-
species variation in TRIM5a accounts for the early restrictions
to retrovirus infection in the cells of primates (Hatziioannou et
al., 2004; Keckesova et al., 2004; Song et al., 2005a, 2005b,0042-6822/$ - see front matter D 2005 Elsevier Inc. All rights reserved.
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1 These authors contributed equally to this work.Stremlau et al., 2004; Yap et al., 2004). Human TRIM5a is
responsible for the postentry restriction of N-tropic murine
leukemia virus (N-MLV) infection in most human cells
(Hatziioannou et al., 2004; Keckesova et al., 2004; Perron et
al., 2004; Yap et al., 2004).
The tripartite motif that defines the TRIM proteins
includes a RING domain, B-box 2 domain, and coiled-coil
domain (Reymond et al., 2001). Many TRIM proteins form
nuclear or cytoplasmic bodies when expressed in cells
(Reymond et al., 2001). Some TRIM proteins, including
TRIM5, contain a C-terminal B30.2 or SPRY domain (Henry
et al., 1998; Reymond et al., 2001). Differential splicing of
the TRIM5 primary transcript gives rise to the expression of
several isoforms of the protein product (Reymond et al.,
2001). The TRIM5a isoform is the largest product (493
amino acid residues in humans) and contains the B30.2/
SPRY domain. The other TRIM5 isoforms lack an intact
B30.2/SPRY domain. The TRIM5g isoform from rhesus
monkeys does not inhibit HIV-1 or SIVmac infection
(Stremlau et al., 2004). Thus, the B30.2 domain is critical5) 201 – 211
www.e
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Mutants of rhesus monkey TRIM5a lacking the RING
domain exhibit reductions in, but not complete loss of, the
ability to block HIV-1 infection (Javanbakht et al., 2005).
TRIM5 proteins are expressed constitutively in many
tissues (Reymond et al., 2001), consistent with the pattern
of expression observed for the HIV-1-blocking factor in
monkeys (Hofmann et al., 1999). One TRIM5 isoform,
TRIM5y, has been shown to localize to cytoplasmic bodies
(Reymond et al., 2001), and is reported to have ubiquitin
ligase activity typical of RING-containing proteins (Xu et al.,
2003). The function of cytoplasmic bodies is unknown; they
do not colocalize with markers for defined organelles
(Reymond et al., 2001). In this study, we examine the
subcellular localization of TRIM5a and investigate the
relationship between TRIM5a cytoplasmic body formation
and retroviral restriction activity.Fig. 1. Expression and subcellular localization of TRIM5a proteins derived from va
expressing TRIM5a proteins from the indicated primate species were seeded in 8-
influenza virus hemagglutinin (HA). Following fixation and permeabilization, the
conjugated with FITC (green). To stain DNA, TOPRO3 (red) was included in
pyg=subspecies pygerythrus; tan=subspecies tantalus. (B) Steady-state levels of T
TRIM5a proteins from the indicated primate species were subjected to Western blo
antibody directed against h-actin.Results
Localization of TRIM5a proteins from different species
Phylogenetic and functional analyses of primate TRIM5a
variants demonstrated species-specific variation in TRIM5a
sequence and in the pattern of restriction against various
retroviruses (Hatziioannou et al., 2004; Keckesova et al.,
2004; Perron et al., 2004; Song et al., 2005a, 2005b;
Stremlau et al., 2004; Yap et al., 2004). The subcellular
localization of various primate TRIM5a proteins was
examined in HeLa cells stably expressing the TRIM5a
proteins (Fig. 1A). All of the primate TRIM5a proteins
exhibited a diffuse cytoplasmic pattern of staining, and some
of the TRIM5a variants formed cytoplasmic bodies of
different sizes and shapes. Both rhesus monkey and human
TRIM5a proteins formed cytoplasmic bodies, with those ofrious primate species. (A) Localization of TRIM5a variants. HeLa cells stably
well chamber slides. The TRIM5a proteins have an epitope tag derived from
cells were incubated with a rat anti-HA antibody followed by an anti-rat IgG
the incubation with the secondary antibody. AGM=African green monkey;
RIM5a expression. Lysates from HeLa cells stably expressing the HA-tagged
tting with an anti-HA antibody. The lysates were also Western blotted with an
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defined compared with those of human TRIM5a. The
TRIM5a proteins of two different subspecies of African
green monkeys formed large, ovoid cytoplasmic bodies,
which in the case of the AGM(pyg) TRIM5a were often
greater than 1 A in diameter. The squirrel monkey TRIM5a
protein was found in large and elongated cytoplasmic bodies
that formed distinctive, wispy patterns. The spider monkey
TRIM5a protein did not form cytoplasmic bodies. These
differences are not explained by variation in the amounts of
the TRIM5a variants expressed in the HeLa cells (Fig. 1B).
We note, however, that the spider monkey TRIM5a protein
exhibits some proteolytic cleavage of its carboxyl terminus,
which may contribute to the lack of cytoplasmic bodies in
the HeLa cells. Because the spider monkey TRIM5a protein
in this cell line retains potent antiretroviral activity (Song et
al., 2005b), the formation of cytoplasmic bodies is apparently
not required for the retroviral restriction activity of at least
some TRIM5a proteins.
Effects of geldanamycin on TRIM5a function and cytoplasmic
body formation
Cytoplasmic bodies formed by TRIM5a also contain
polyubiquitylated proteins and components of the unfolded
protein response (Diaz-Griffero et al., submitted for publica-
tion). During the course of our studies, we observed that
geldanamycin, an inhibitor of the heat shock protein Hsp90
(Whitesell et al., 1994), could influence the appearance of
TRIM5-containing cytoplasmic bodies. HeLa cells stably
expressing the TRIM5a proteins of rhesus monkeys, African
green monkeys, and squirrel monkeys were treated with
geldanamycin or the DMSO solvent control for either 2 or
14 h. After geldanamycin treatment, rhesus monkey TRIM5a
exhibited diffuse cytoplasmic staining, but did not form
cytoplasmic bodies (Fig. 2A). The cytoplasmic bodies formed
by African green monkey and squirrel monkey TRIM5a
proteins were greatly reduced in size and number by
geldanamycin treatment (Fig. 2A). The steady-state levels of
the TRIM5a proteins in the HeLa cells were not significantly
affected by geldanamycin treatment (Fig. 2B). Similar results
were obtained with two other Hsp90 inhibitors, novobiocin and
herbimycin A (Loo et al., 1998; Yun et al., 2004) (data not
shown). Thus, treatment of cells with certain Hsp90 inhibitors
can reduce or eliminate the association of TRIM5a with
cytoplasmic bodies.
To examine the contribution of cytoplasmic body formation
to TRIM5a antiviral function, TRIM5a-expressing or control
HeLa cells were treated with geldanamycin for 2 h prior to
incubation with recombinant HIV-1 expressing GFP (Fig. 2C).
In parallel experiments, cells were treated with geldanamycin
for 2 h prior to and 12 h following the introduction of virus
(Fig. 2D). In neither case did geldanamycin treatment
significantly affect the ability of the TRIM5a proteins of
rhesus monkeys or African green monkeys (two Old World
monkey species) to restrict HIV-1 infection. HIV-1 infection of
cells transduced with the empty LPCX vector or cellsexpressing human or squirrel monkey TRIM5a proteins was
not significantly affected by geldanamycin treatment. These
results demonstrate that the incorporation of TRIM5a into
cytoplasmic bodies is not absolutely required for antiretroviral
activity.
Characterization of TRIM5a cytoplasmic bodies by electron
microscopy
The association of rhesus monkey TRIM5a with cyto-
plasmic bodies and the effects of geldanamycin treatment
were examined by electron microscopy. HeLa cells stably
expressing HA-tagged rhesus monkey TRIM5a were fixed
and sectioned. The sections were labeled with an anti-HA
antibody and gold particles conjugated to Protein A.
Cytoplasmic bodies containing the TRIM5a protein were
apparent in the TRIM5a-expressing cells (Figs. 3A–F), but
not in control HeLa cells (data not shown). The cytoplasmic
bodies varied in shape and size, ranging in diameter from 40
to 120 nm.
Treatment of the HeLa cells expressing rhesus monkey
TRIM5a with geldanamycin resulted in a complete loss of
detectable TRIM5a-associated cytoplasmic bodies (Figs. 3G
and H and Table 1). After geldanamycin treatment, diffusely
scattered immunogold particles were observed in the cyto-
plasm and also in the nucleus. These results confirm that
geldanamycin treatment of HeLa cells expressing rhesus
monkey TRIM5a leads to a loss of association with
cytoplasmic bodies.
Investigation of TRIM5a determinants important for
cytoplasmic body incorporation
To investigate whether specific rhesus monkey TRIM5a
domains are required for incorporation into cytoplasmic
bodies, various constructs were created with a green fluores-
cent protein (GFP) fused at the amino terminus of full-length
or deleted versions of TRIM5a (Fig. 4). Upon transient
expression in HeLa cells, GFP–TRIM5a fusion proteins were
detected using fluorescence microscopy (Fig. 5). As was
observed for the HA epitope-tagged protein, the GFP–
TRIM5a fusion protein exhibited diffuse cytoplasmic staining
and also formed discrete cytoplasmic bodies. By contrast, the
GFP control exhibited strong nuclear staining as well as
cytoplasmic staining. GFP–TRIM5a fusion proteins with
deletions of the RING domain (97–497), the RING domain
and B-box 2 (132–497), or the RING domain, B-box 2 and
coiled coil (297–497) exhibited indistinguishable patterns of
staining; these proteins, as well as two proteins retaining the
TRIM5a coiled coil (132–296 and 132–233), exhibited
intense, diffuse staining in some cells and diffuse cytoplasmic
staining with the formation of cytoplasmic bodies in most
cells (Fig. 5). Deletion of the B30.2 domain (1–296) or
deletion of the B30.2 domain and the linker region between
the coiled coil and B30.2 domain (1–233) had no effect on
cytoplasmic body formation or on diffuse cytoplasmic
localization of the protein. These results suggest that no
B. Song et al. / Virology 343 (2005) 201–211204specific domain of rhesus monkey TRIM5a is required for the
formation of cytoplasmic bodies.
To determine whether the cytoplasmic bodies formed by the
truncated TRIM5 variants correspond to those formed by the
wild-type TRIM5a protein, colocalization of the GFP–
TRIM5a variants and a red fluorescent protein (RFP) fused
with the wild-type rhesus monkey TRIM5a (RFP–TRIM5a)
was examined (Fig. 6). HeLa cells were transfected withplasmids expressing pRFP–TRIM5a and pGFP–TRIM5
variants and examined using a confocal microscope. As shown
in Fig. 6, RFP–TRIM5a colocalized with the cytoplasmic
bodies formed by all of the GFP–TRIM5 variants. The intense,
diffuse staining observed in some of the cells expressing the
97–497, 132–497, 297–497, and 132–296 fusion proteins did
not colocalize with RFP–TRIM5a protein. We conclude that
the cytoplasmic bodies formed by the truncated TRIM5a
Fig. 2. Effects of geldanamycin on cytoplasmic body formation and anti-retroviral activity of TRIM5a. (A) Geldanamycin disrupts TRIM5a cytoplasmic bodies.
HeLa cells stably expressing rhesus monkey, AGM(tan), or squirrel monkey TRIM5a proteins were treated for 2 or 14 h with either geldanamycin (10 AM) or the
DMSO solvent as a control. The cells were fixed, incubated with the anti-HA antibody and the secondary antibody conjugated with FITC, and examined using a
fluorescence microscope. (B) Expression of TRIM5a proteins in the cells treated with geldanamycin. HeLa cells stably expressing the indicated primate TRIM5a
proteins were treated with DMSO as a control or geldanamycin (10 AM) for 14 h. Cell lysates were then processed for Western blotting with an antibody against HA
for TRIM5a expression and with an antibody against h-actin as a control. (C) Effects of geldanamycin on TRIM5a restriction. HeLa cells expressing the vector
control or the indicated TRIM5a proteins were seeded in 24-well plates and treated for 2 h with geldanamycin (10 AM) or DMSO as a control. Then, the cells were
incubated with 40,000 cpm of reverse transcriptase activity of HIV-1–GFP for 12 to 16 h. Cells were washed and returned to culture for 48 h and then analyzed by
fluorescence-activated cell sorter (FACS) for GFP expression. The results of a typical experiment are shown. Similar results were obtained in three independent
experiments. (D) Geldanamycin effects on anti-HIV-1 activity of TRIM5a. HeLa cells expressing the vector control or the indicated TRIM5a proteins were treated
for 2 h with geldanamycin or the DMSO solvent control. The cells were then incubated with HIV-1–GFP for 12 h, during which time geldanamycin or DMSO
treatment was continued. Next, the cells were washed and, 48 h after the beginning of virus incubation, analyzed for GFP expression. The results shown are typical of
those obtained in three experiments.
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Fig. 3. Detection of cytoplasmic bodies by electron microscopy. HeLa cells expressing rhesus monkey TRIM5a were fixed and ultrathin sections were prepared.
Sections were labeled with an anti-HA antibody and Protein A-gold (10 nm particles). Cytoplasmic bodies are shown in A–F. HeLa cells that were treated with
DMSO solvent as a control (G) or geldanamycin (H) and then processed as described above are shown. The arrow indicates a cytoplasmic body. nu=nucleus;
PM=plasma membrane.
B. Song et al. / Virology 343 (2005) 201–211206proteins coincide with the bodies formed by wild-type rhesus
monkey TRIM5a.
Discussion
Many TRIM proteins, when overexpressed in cells, form
cytoplasmic or nuclear bodies (Reymond et al., 2001). As the
function of most cytoplasmic TRIM proteins is unknown, the
contribution of cytoplasmic body formation to TRIM function
has not been explored. The ability of TRIM5a proteins from
different primate species to restrict infection by various
retroviruses (Hatziioannou et al., 2004; Keckesova et al.,
2004; Perron et al., 2004; Song et al., 2005b; Stremlau et al.,
2004; Yap et al., 2004), and the evidence for positive
evolutionary selection of TRIM5 genes (Sawyer et al., 2005;
Song et al., 2005a) support the possibility that a major natural
function of TRIM5a is its antiviral activity. We investigated the
potential contribution of cytoplasmic body formation toretrovirus restriction by TRIM5a. Our results argue against a
necessary role for TRIM5a association with cytoplasmic
bodies in its antiretroviral activity. First, some TRIM5a
proteins, exemplified by spider monkey TRIM5a, do not form
cytoplasmic bodies when expressed in cultured cells. None-
theless, spider monkey TRIM5a in these cells potently blocks
infection by SIVmac, SIVagm and HIV-1 (Song et al., 2005b).
Second, treatment of cells expressing rhesus monkey TRIM5a
with an Hsp90 inhibitor, geldanamycin, resulted in the
complete disappearance of TRIM5a-associated cytoplasmic
bodies. Nonetheless, HIV-1 infection was blocked in the
geldanamycin-treated TRIM5a-expressing cells with an effi-
ciency similar to that observed in untreated cells. Finally, we
have previously observed that a RING domain-deleted version
of rhesus monkey TRIM5a forms nuclear, not cytoplasmic,
bodies (Javanbakht et al., 2005); the portion of this protein that
remains in the cytosol exhibits a diffuse staining pattern. This
RING domain-deleted TRIM5a mutant retains partial activity
Table 1
Effect of geldanamycin on immunogold detection of TRIM5a-associated
cytoplasmic bodies
Cytoplasmic
bodies per
2000 cellsa
Average
diameter of
cytoplasmic
bodies (nm)
Localization of
immunogold
particles
TRIM5arh-HA
without geldanamycin
50 82 (1) Cytoplasmic
bodies
(2) Diffuse
cytoplasmic
TRIM5arh-HA
with geldanamycin
0 – (1) Diffuse
cytoplasmic
(2) Diffuse
nuclear
a HeLa cells stably expressing rhesus monkey TRIM5a were treated for
12 h with 10 AM geldanamycin or with the DMSO solvent control. Cells were
fixed, sectioned and stained with an anti-HA antibody and Protein A-gold, as
described in Materials and Methods. The cytoplasmic bodies were defined as
collections of greater than 10 immunogold particles, and were counted in 2000
cells.
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cytoplasmic bodies are not per se necessary for the antire-
troviral function of TRIM5a. Rather, the more dispersed
cytoplasmic TRIM5a protein probably constitutes the active
fraction.
In other studies (Diaz-Griffero et al., submitted for
publication), we have shown that TRIM5a is polyubiquitylated
and rapidly degraded by the proteosome. The TRIM5a
cytoplasmic bodies were observed to coalesce into structures
that resemble aggresomes (Garcia-Mata et al., 2002; Johnston
et al., 1998) after treatment of expressing cells with proteosome
inhibitors. Nocodazole, which inhibits microtubule-dependent
transport of protein aggregates to the aggresome, causes
TRIM5a cytoplasmic bodies to expand in size. Thus, it appears
that cytoplasmic bodies represent collections of TRIM5a
proteins destined either for deaggregation or for transport to
the aggresome. In this study, we demonstrate that TRIM5aFig. 4. GFP-TRIM5a constructs. GFP is fused to full-length (wt) rhesus monkey T
indicated, with the amino acid residue numbers shown on the full-length TRIM5acytoplasmic bodies disappear or are reduced in number after
treatment of cells with geldanamycin. Geldanamycin inhibits
Hsp90 (Loo et al., 1998; Whitesell et al., 1994), a heat shock
protein that acts as a chaperone to promote protein folding and
that has been shown to be associated with both aggresomes
(Garcia-Mata et al., 2002; Johnston et al., 1998; Riley et al.,
2003) and TRIM5a cytoplasmic bodies (Diaz-Griffero et al.,
submitted for publication). How Hsp90 inhibition leads to
dissolution of the cytoplasmic bodies is unclear, but is worthy
of additional investigation.
Cytoplasmic bodies presumably reflect the ability of TRIM
proteins to associate with themselves or heterologous proteins.
That homo-oligomerization and propensity to aggregate are
common features of TRIM proteins in general (Reymond et
al., 2001) suggests that these characteristics are intrinsic to
their function. The contribution of TRIM5a self-association to
its antiviral function is unknown. No single TRIM5a domain
was essential for association with cytoplasmic bodies. In light
of the relationship of cytoplasmic bodies to aggresomes
discussed above, it appears that more than one element of
TRIM5a can participate in self-association. One caveat in
interpreting the contribution of particular domains to TRIM5
localization is that proteins with missing or disrupted domains
may be more prone to aggregation due to lack of natural
interdomain interactions. Future studies should shed light on
how each of the TRIM5a domains contributes to its antiviral
function.
Materials and methods
Cells and antibodies
HeLa cells were obtained from the American Type Culture
Collection. The generation of cDNAs containing the amino-
acid-coding sequence of various primate TRIM5a genes was
described previously (Song et al., 2005b). Cells stablyRIM5a or to the indicated segments of TRIM5a. The TRIM5a domains are
protein.
Fig. 5. Intracellular location of GFP–TRIM5a constructs. HeLa cells were seeded in 12-well plates and transfected with 1–2 Ag of pGFP–TRIM5a plasmids
encoding GFP fused to the indicated rhesus monkey TRIM5a segments. Twenty-four h after transfection, the cells were subcultured into 8-well chamber slides and
incubated for another 24 h. The cells were fixed and examined using a fluorescence microscope. The GFP expression vector, pEGFP-C1, was included as a control
(designated GFP).
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viral transduction system. Retroviral vectors encoding the
TRIM5a variants were created using the pLPCX vector
(Stratagene). The pLPCX–TRIM5a vectors contain only the
amino-acid-coding sequence of the TRIM5a cDNA. With the
exception of human TRIM5a, the TRIM5a proteins possess
N-terminal epitope tags derived from influenza virus hemag-
glutinin (HA). In the human TRIM5a, the HA tag is at the
C-terminus. Recombinant viruses were produced in 293T
cells by cotransfecting these pLPCX plasmids with the
pVPack-GP and pVPack-VSV-G packaging plasmids (Strata-
gene). The pVPack-VSV-G plasmid encodes the vesicular
stomatitis virus (VSV) G envelope glycoprotein, which
allows efficient entry into a wide range of vertebrate cells
(Beyer et al., 2002; Hofmann et al., 1999; Yee et al., 1994).
The resulting virus particles were used to transduce ~1105
HeLa cells in the presence of polybrene (5 Ag/ml). Cells
were selected in medium supplemented with 1 Ag/ml of
puromycin (Sigma). The rat anti-HA antibody 3F10 was
obtained from Roche. The anti-rat IgG conjugated with FITC
was obtained from Santa Cruz. TOPRO3, which was used to
stain DNA, was obtained from Molecular Probes. Geldana-mycin (Sigma) was solubilized in DMSO at a 1 mM stock
concentration and used at a final concentration of 10 AM.
Novobiocin (Sigma) was solubilized in water at a 1 mM
stock concentration and used at a final concentration of 10
AM. Herbimycin A (Sigma) was solubilized in DMSO at a 1
mg/ml stock concentration and used at a final concentration
of 10 Ag/ml.
Western blotting
Steady-state levels of TRIM5a proteins in the cell were
determined by Western blotting with an anti-HA antibody, as
described previously (Song et al., 2005b).
Immunofluorescence confocal microscopy
HeLa cells in 12-well plates were transfected with 1–2 Ag
of the pGFP–TRIM5a or pRFP–TRIM5a plasmids for 24
h using Gene Porter 2 (GTS, San Diego), and then
subcultured on 8-well chamber slides. Twenty-four hours later,
the cells were fixed and examined by confocal fluorescence
microscopy.
Fig. 6. Colocalization of GFP–TRIM5a variants and RFP–TRIM5a. HeLa cells were transfected with the pRFP–TRIM5a plasmid encoding a fusion protein of
RFP and full-length rhesus monkey TRIM5a and pGFP–TRIM5a plasmids encoding GFP fused with the full-length or indicated truncated forms of rhesus monkey
TRIM5a. Colocalization of the GFP–TRIM5a variants and RFP–TRIM5a was examined using a confocal fluorescence microscope.
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WT (f): 5V-gcgctcgaggcgcttctggaatcctgcttaatgta-3V
WT (r): 5V-gcggggcccgctcaagagcttggtgagcacagagt-3V
97–497 (f): 5V-gcgctcgaggctgtgcacgccatggagagaaactc-3V
97–497 (r): 5V-gcggggcccgctcaagagcttggtgagcacagagt-3V
132–497 (f): 5V-gcgctcgaggcctcatggaggaggttgcccaggag-3V
132–497 (r): 5V-gcggggcccgctcaagagcttggtgagcacagagt-3V
297–497 (f): 5V-gcgctcgaggccgacgctactgggttgatgtgaca-3V
297–497 (r): 5V-gcggggcccgctcaagagcttggtgagcacagagt-3V
132–296 (f): 5V-gcgctcgaggcctcatggaggaggttgcccaggag-3V
132–296 (r): 5V-gcggggcccgctcaggcatctgttagctctctaaa-3V
132–233 (f): 5V-gcgctcgaggcctcatggaggaggttgcccaggag-3V
132–233 (r): 5V-gcggggcccgctcagagctctctcatgtactgggt-3V
1–296 (f): 5V-gcgctcgaggcgcttctggaatcctgcttaatgta-3V
1–296 (r): 5V-gcggggcccgctcaggcatctgttagctctctaaa-3V
1–233 (f): 5V-gcgctcgaggcgcttctggaatcctgcttaatgta-3V
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were similarly cultured on 8-well chamber slides. Following
fixation and permeabilization, the cells were incubated with rat
anti-HA 3F10 antibody followed by secondary anti-rat IgG
conjugated with FITC to detect the expression of the TRIM5a
protein, and examined by confocal fluorescence microscopy.
To stain DNA, TOPRO3 (1:200) was included in the reaction
with the secondary antibody.
Infection with viruses expressing GFP
Recombinant viruses (HIV-1–GFP and SIVmac–GFP)
expressing the humanized Renilla reniformis green fluores-
cent protein (GFP) were prepared as previously described
(Perron et al., 2004; Stremlau et al., 2004). The viral stocks
were quantified by measuring reverse transcriptase activity, as
described previously (Rho et al., 1981). For infection, HeLa
cells expressing the TRIM5a variants were seeded in a 24-
well plate and incubated with 2–4104 cpm of HIV-1–GFP
viruses for 12 to 16 h. Cells were washed and returned to
culture for 48 h and then subjected to fluorescence-activated
cell sorter (FACS) analysis with a FACScan (Becton
Dickinson).
Geldanamycin treatment of cells expressing TRIM5a
HeLa cells stably expressing HA-tagged TRIM5a variants
were cultured on 8-well chamber slides. The cells were treated
with geldanamycin (Sigma) at 10 AM or with DMSO as a
control for either 2 h or 14 h. Following fixation and
permeabilization, the cells were incubated with rat anti-HA
3F10 antibody (Roche) followed by secondary anti-rat IgG
conjugated with FITC to detect the expression of the TRIM5a
protein, and examined by fluorescence microscopy.
To determine the effects of geldanamycin on TRIM5a
restriction of HIV-1–GFP infection, HeLa cells stably
expressing HA-tagged TRIM5a variants were cultured in
24-well plates and treated with geldanamycin at 10 AM or
with DMSO as a control for 2 h prior to infection, or 2 h prior
to infection and another 12 h during infection. The cells were
washed and refed with fresh medium. Forty-eight h after
infection, the cells were harvested and analyzed by FACS for
GFP expression.
Detection of TRIM5a by electron microscopy
HeLa cells stably expressing HA-tagged rhesus monkey
TRIM5a were removed from the tissue culture dish with 5
mM EDTA in PBS, pelleted, and resuspended in a small
volume of 4% paraformaldehyde in 0.2 M sodium phosphate
buffer, pH 7.4. Ultrathin sections were cut at 120-C with a
cryo-diamond knife. Sections were picked up from the knife
with a loop dipped in a 1:1 mixture of 2.3 M sucrose and 2%
methylcellulose and transferred to a carbon-coated copper
grid. Grids were left floating on PBS with the section facing
down. Grids were washed in PBS and blocked in 1% bovine
serum albumin (BSA) in PBS for 15 min. Grids were thenincubated with the anti-HA 3F10 antibody (Roche) in 1%
BSA in PBS for 30 min and washed four times for 15 min in
PBS. Then, the grids were incubated with Protein A-gold 10
nm particles (Jackson Immunoresearch) in 1% BSA in PBS
for 20 min and washed four times for 15 min in PBS. Images
were acquired using a transmission electron microscope JEOL
1200EX-80kV.
Construction of GFP-TRIM5a plasmids
PCR-amplified segments encoding the wild-type or trun-
cated rhesus monkey TRIM5a proteins were inserted into
pEGFP-C1 (Clontech) to create pGFP-TRIM5a, which
encodes a fusion protein with GFP fused at the amino
terminus of TRIM5a. An amplified segment encoding the
wild-type rhesus monkey TRIM5a protein was inserted into
pDsRed2-C1 (Clontech) to create pRFP-TRIM5a, which
encodes a fusion protein with RFP fused at the amino
terminus of TRIM5a. The wild-type rhesus monkey TRIM5a
protein is 497 amino acid residues in length. GFP-TRIM5a
fusion proteins were created with deletions of particular
TRIM5a domains. The 97–497 construct is missing the
RING domain; the 132–497 construct is missing the RING
domain and the B-box 2 domain; the 297–497 construct
contains only the B30.2 domain. The 132–296 construct
contains the coiled coil domain and the linker region between
the coiled coil and B30.2 domains. The 132–233 construct
contains only the coiled coil domain. The 1–296 construct
lacks the B30.2 domain and the linker region. The PCR
primers used to amplify each of the rhesus monkey TRIM5a
constructs are listed below. Forward (f) primers contain an
XhoI site and reverse (r) primers contain an ApaI site for
cloning into the XhoI and ApaI sites of pEGFP-C1 or
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